Compare SBSI & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBSI | CTMX |
|---|---|---|
| Founded | 1960 | 2008 |
| Country | United States | United States |
| Employees | 781 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.1M | 977.1M |
| IPO Year | 1995 | 2015 |
| Metric | SBSI | CTMX |
|---|---|---|
| Price | $32.79 | $3.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $35.33 | $12.10 |
| AVG Volume (30 Days) | 64.2K | ★ 2.8M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $28.87 | N/A |
| Revenue Next Year | $5.82 | $7.61 |
| P/E Ratio | $42.18 | ★ $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.32 | $1.72 |
| 52 Week High | $34.53 | $8.21 |
| Indicator | SBSI | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 39.49 |
| Support Level | $31.82 | $3.39 |
| Resistance Level | $34.06 | $3.91 |
| Average True Range (ATR) | 0.70 | 0.20 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 52.80 | 39.76 |
Southside Bancshares Inc is a bank holding company. Through its subsidiary, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.